Skip to main content

Advertisement

Table 3 Overview of demographic and clinical data as well as inter-group comparisons for the cohorts NMCLRRK2 and CON stratified by gender

From: Inflammatory profile in LRRK2-associated prodromal and clinical PD

  Female N = 152 Male N = 96 Female Male
  NMCLRRK2 N = 63 CON N = 89 NMCLRRK2 N = 52 CON N = 44 p value NMCLRRK2 CON p value NMCLRRK2 CON
Age Years 51 23–84 57 18–83 54 27–82 58 28–83 0.087 0.110
UPDRS-III 0 0–13 0 0–9 0 0–15 0 0–8 0.021 0.542
MoCA 28 18–30 27 17–30 27 18–30 27 17–30 0.756 0.809
RBD Questionnaire 1 0–9 1 0–13 2 0–9 1 0–11 0.396 0.943
ESS 6 0–15 6 0–15 5 0–15 6 0–14 0.948 0.399
SCOPA-AUT 8 1–33 7 0–41 7 0–39 6 0–30 0.221 0.729
Regular anti-inflammatory medication (% of individuals) 3.7 1.2 4.6 0.0 0.561 0.495
  1. Data are presented as median with range. p values reflect results from Mann–Whitney test. The intake of anti-inflammatory medication is given as % of individuals from the respective cohort; statistical analysis was done using chi-square test
  2. NMC LRRK2 non-manifesting LRRK2 mutation carriers, CON healthy control individuals, ESS Epworth Sleepiness Scale, HY Hoehn and Yahr Scale, LEDD levodopa-equivalent daily dosage, MoCA Montreal Cognitive Assessment, RBD REM sleep behavior disorder, UPDRS-III Unified Parkinson’s disease Rating Scale